13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Opsumit improves right ventricular function in PAH patients

Actelion Ltd. said Opsumit macitentan significantly improved right ventricular function and pulmonary vascular resistance at week 26 compared with baseline in the open-label Phase IV REPAIR trial in patients with symptomatic pulmonary arterial hypertension. The...
22:13 , Feb 22, 2019 |  BC Extra  |  Politics & Policy

China releases list of rare disease drugs with reduced VAT

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...
16:56 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting MENA could help treat metastases of serous ovarian cancer. In a panel of serous ovarian cancer cell lines, expression of the MENA isoform MENAΔv6 was...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
03:07 , Feb 4, 2017 |  BioCentury  |  Strategy

Actelion, take two

After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse. Johnson & Johnson ’s proposed $30 billion...
23:55 , Jan 27, 2017 |  BioCentury  |  Finance

Patience pays off

Nearly six years after shareholders rebuffed an activist investor’s proposal to sell Actelion Ltd. (SIX:ATLN), CEO Jean-Paul Clozel has made good on his promise that the biotech could build more value if investors waited for...
23:27 , Jan 27, 2017 |  BC Week In Review  |  Company News

J&J, Actelion deal

Johnson & Johnson will acquire Actelion for $280 per share in cash, or about $30 billion. Based on current exchange rates, the price is a 23% premium to Actelion's closing price of CHF227.40 on Jan....
04:31 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Opsumit: Ph III MAESTRO data

Top-line data from the double-blind, international Phase III MAESTRO trial in 226 patients with PAH due to Eisenmenger syndrome in the intent-to-treat (ITT) population showed that once-daily 10 mg oral Opsumit missed the primary endpoint...
00:44 , Jan 27, 2017 |  BC Extra  |  Company News

J&J acquiring Actelion, spinning out newco

Johnson & Johnson (NYSE:JNJ) will acquire Actelion Ltd. (SIX:ATLN) for $280 per share in cash, or about $30 billion. Based on current exchange rates, the price is a 23% premium to Actelion's closing price Wednesday...